JP7105505B2 - 生体組織への局所曝露方法、組織置換アプリケーターおよび多孔質ポリテトラフルオロエチレンの使用 - Google Patents
生体組織への局所曝露方法、組織置換アプリケーターおよび多孔質ポリテトラフルオロエチレンの使用 Download PDFInfo
- Publication number
- JP7105505B2 JP7105505B2 JP2020529386A JP2020529386A JP7105505B2 JP 7105505 B2 JP7105505 B2 JP 7105505B2 JP 2020529386 A JP2020529386 A JP 2020529386A JP 2020529386 A JP2020529386 A JP 2020529386A JP 7105505 B2 JP7105505 B2 JP 7105505B2
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- tumor
- tissue replacement
- porous ptfe
- applicator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001343 polytetrafluoroethylene Polymers 0.000 title claims description 66
- 239000004810 polytetrafluoroethylene Substances 0.000 title claims description 66
- -1 polytetrafluoroethylene Polymers 0.000 title claims description 8
- 238000000034 method Methods 0.000 title description 21
- 231100000936 topical exposure Toxicity 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 49
- 229920000642 polymer Polymers 0.000 claims description 6
- 230000001085 cytostatic effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 description 103
- 206010018338 Glioma Diseases 0.000 description 33
- 208000032612 Glial tumor Diseases 0.000 description 29
- 241000700157 Rattus norvegicus Species 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 25
- 238000002513 implantation Methods 0.000 description 23
- 210000005013 brain tissue Anatomy 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 239000002245 particle Substances 0.000 description 15
- 210000003710 cerebral cortex Anatomy 0.000 description 13
- 239000002105 nanoparticle Substances 0.000 description 11
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 210000004126 nerve fiber Anatomy 0.000 description 10
- 230000005291 magnetic effect Effects 0.000 description 9
- 206010020843 Hyperthermia Diseases 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000036031 hyperthermia Effects 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 102100033639 Acetylcholinesterase Human genes 0.000 description 7
- 108010022752 Acetylcholinesterase Proteins 0.000 description 7
- 230000002518 glial effect Effects 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 125000002091 cationic group Chemical group 0.000 description 6
- 230000001713 cholinergic effect Effects 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000010826 Nissl staining Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 210000004884 grey matter Anatomy 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 5
- 230000002025 microglial effect Effects 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 4
- 230000005294 ferromagnetic effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 210000000944 nerve tissue Anatomy 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000002327 eosinophilic effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000009510 cerebral cortex damage Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 229950003937 tolonium Drugs 0.000 description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000004035 construction material Substances 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002977 hyperthermial effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011553 magnetic fluid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000021715 photosynthesis, light harvesting Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000012196 polytetrafluoroethylene based material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000005245 sintering Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000133 toxic exposure Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/755—Polymers containing halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0059—Cosmetic or alloplastic implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L27/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers
- C08L27/02—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers not modified by chemical after-treatment
- C08L27/12—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen; Compositions of derivatives of such polymers not modified by chemical after-treatment containing fluorine atoms
- C08L27/18—Homopolymers or copolymers or tetrafluoroethene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth
- A61F2002/009—Special surfaces of prostheses, e.g. for improving ingrowth for hindering or preventing attachment of biological tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Description
この出願の発明に関連する先行技術文献情報としては、以下のものがある(国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む)。
(先行技術文献)
(特許文献)
(特許文献1) 欧州特許出願公開第0194446号明細書
(特許文献2) 米国特許出願公開第2014/308336号明細書
(特許文献3) 国際公開第2017/120608号
(特許文献4) ロシア国特許発明第2497489号明細書
実施例1
腫瘍および健康な細胞に対する多孔質PTFE細胞毒性を測定するために、2つのシリーズのin vitro試験が行われた。
腫瘍細胞を培地(この研究ではC6神経膠腫)に導入した。1つの培地部分は参照用にそのまま残し、もう1つは多孔質PTFE組織置換アプリケーターを配置した。
-C6神経膠腫無傷細胞分布(図2a、70±3%コンフルエンス)および多孔質PTFE組織置換アプリケーターの配置後のC6神経膠腫細胞分布(図2b、20±4%コンフルエンス);
-C6神経膠腫無傷細胞単層、トリパンブルー染色(図3a、C6神経膠腫無傷細胞生存率-90±3%)、および多孔質PTFE組織置換アプリケーターを備えたC6神経膠腫細胞単層(図3b、多孔質PTFE組織置換アプリケーターでのC6神経膠腫細胞の生存率-55±3%)
健康な細胞を培地(この研究では、線維芽細胞)に導入した。1つの培地部分は参照用にそのまま残し、もう1つは多孔質PTFE組織置換アプリケーターを配置した。
-無傷の線維芽細胞の分布(図4a、53±3%コンフルエンス)および多孔質PTFE組織置換アプリケーターの配置後の線維芽細胞の分布(図4b、35±4%コンフルエンス);
-無傷の線維芽細胞単層、トリパンブルー染色(図5a、無傷の線維芽細胞の生存率-99±3%)、および多孔質PTFE組織置換アプリケーターを備えた線維芽細胞単層(図5b、多孔質PTFE組織置換アプリケーターを備えた線維芽細胞生存率-98±3%)。
in vivo試験は、ウィスターラットの大脳皮質テストに焦点を当て、3つのグループに分けられた:グループ1-C6神経膠腫異種移植片が感覚運動皮質に1ヶ月(30日間)移植されたラット、グループ2-C6神経膠腫異種移植片と多孔質PTFE組織置換アプリケーターが感覚運動皮質に1ヶ月(30日間)移植されたラット、グループ3-多孔質PTFE組織置換アプリケーターのみが感覚運動皮質に1ヶ月(30日間)移植されたラット。
感覚運動皮質に多孔質PTFE組織置換アプリケーターまたはC6神経膠腫と多孔質PTFE組織置換アプリケーターを移植した後の4ヶ月の追跡におけるウィスターラット脳組織の組織学的分析。
実験ラットの腫瘍大脳皮質組織への移植後4ヶ月後、多孔質PTFE組織置換アプリケーターは、融解壊死の複数の小さな病巣と腫瘍組織崩壊の巨大な中心病巣の形成に利益をもたらし、それにより腫瘍の縮小をもたらす。
実験用ラットの腫瘍大脳皮質組織への移植後4ヶ月後、多孔質PTFE組織置換アプリケーターは、融解壊死の複数の小さな病巣と腫瘍組織崩壊の巨大な中心病巣の形成に利益をもたらし、結果として腫瘍の縮小をもたらす。
Claims (3)
- 腫瘍の治療用の組織置換ポリマー移植物であって、多孔質ポリテトラフルオロエチレンで構成され、腫瘍組織又は前記腫瘍組織の周辺組織 と直接接触して配置されるためのものである、組織置換ポリマー移植物。
- 前記組織置換ポリマー移植物が、前記腫瘍組織に対して細胞増殖抑制効果を発揮する、請求項1に記載の組織置換ポリマー移植物。
- 腫瘍の治療または腫瘍組織の置換の ための組織置換ポリマー移植物の製造における多孔質ポリテトラフルオロエチレンの使用。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/BY2017/000018 WO2019104407A1 (en) | 2017-11-30 | 2017-11-30 | Method of local exposure to biological tissues, tissue-substitute applicator and use of porous polytetrafluoroethylene |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021511092A JP2021511092A (ja) | 2021-05-06 |
JP7105505B2 true JP7105505B2 (ja) | 2022-07-25 |
Family
ID=60953508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020529386A Active JP7105505B2 (ja) | 2017-11-30 | 2017-11-30 | 生体組織への局所曝露方法、組織置換アプリケーターおよび多孔質ポリテトラフルオロエチレンの使用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US11266682B2 (ja) |
EP (1) | EP3717035B1 (ja) |
JP (1) | JP7105505B2 (ja) |
KR (1) | KR102436620B1 (ja) |
CN (1) | CN111526897A (ja) |
BR (1) | BR112020009444A2 (ja) |
CA (1) | CA3098243A1 (ja) |
EA (1) | EA202000158A1 (ja) |
IL (1) | IL274514B2 (ja) |
WO (1) | WO2019104407A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016516780A (ja) | 2013-04-10 | 2016-06-09 | マサチューセッツ インスチテュート オブ テクノロジーMassachusetts Institute Of Technology | 癌治療のための薬物局所送達装置及び方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5968556U (ja) * | 1982-10-25 | 1984-05-09 | 株式会社潤工社 | 加温がん治療用冷却器 |
DE19702898A1 (de) * | 1996-04-04 | 1998-07-23 | Somatex Medizintechnische Inst | Laser-Applikationskatheter |
RU10325U1 (ru) | 1998-12-17 | 1999-07-16 | Мандрик Иван Иванович | Накопитель для монет |
US6997863B2 (en) | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US8119165B2 (en) | 2002-02-14 | 2012-02-21 | Peyman Gholam A | Method and composition for hyperthermally treating cells |
BY10325C1 (en) | 2002-04-23 | 2003-12-30 | Closed Joint Stock Company | Method for producing a porous implant from titanium powder |
US7803178B2 (en) | 2004-01-30 | 2010-09-28 | Trivascular, Inc. | Inflatable porous implants and methods for drug delivery |
EP2638147A2 (en) * | 2010-11-09 | 2013-09-18 | Lonza Cologne GmbH | Method for controlling binding of cells to a substrate |
EP2741775B1 (en) * | 2011-08-11 | 2017-01-04 | Quest Pharmatech Inc. | Polymeric nanoparticles for photosensitizers |
RU2497489C1 (ru) * | 2012-06-04 | 2013-11-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кемеровский технологический институт пищевой промышленности" | Способ локального индукционного нагрева биологических тканей |
RU2506971C1 (ru) | 2012-09-21 | 2014-02-20 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации | Способ подавления опухолевого роста в эксперименте |
WO2017120608A1 (en) | 2016-01-08 | 2017-07-13 | Anton Mark A | COMPOSITE ePTFE AND SILICONE SOFT TISSUE IMPLANTS TO MINIMIZE CAPSULAR CONTRACTURE, WEIGHT, INFECTION AND PALPABILITY |
-
2017
- 2017-11-30 BR BR112020009444-7A patent/BR112020009444A2/pt not_active Application Discontinuation
- 2017-11-30 JP JP2020529386A patent/JP7105505B2/ja active Active
- 2017-11-30 EA EA202000158A patent/EA202000158A1/ru unknown
- 2017-11-30 CA CA3098243A patent/CA3098243A1/en active Pending
- 2017-11-30 CN CN201780098034.0A patent/CN111526897A/zh active Pending
- 2017-11-30 KR KR1020207017583A patent/KR102436620B1/ko active IP Right Grant
- 2017-11-30 IL IL274514A patent/IL274514B2/en unknown
- 2017-11-30 WO PCT/BY2017/000018 patent/WO2019104407A1/en unknown
- 2017-11-30 EP EP17826412.3A patent/EP3717035B1/en active Active
-
2020
- 2020-05-29 US US16/887,100 patent/US11266682B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016516780A (ja) | 2013-04-10 | 2016-06-09 | マサチューセッツ インスチテュート オブ テクノロジーMassachusetts Institute Of Technology | 癌治療のための薬物局所送達装置及び方法 |
Non-Patent Citations (3)
Title |
---|
Neurol. Med. Chir. (Tokyo), (2013), 53, [1], p.43-46 |
Polytetrafluoroethylene implant, [online], (2002),DermNet NZ,[Retrieved on 2021-Sep-22], Retrieved from the internet:<https://dermnetnz.org/topics/polytetrafluoroethylene-implant> |
人工臓器, (1972), 1, [1], p.44-47 |
Also Published As
Publication number | Publication date |
---|---|
EP3717035A1 (en) | 2020-10-07 |
IL274514B2 (en) | 2024-04-01 |
EA202000158A1 (ru) | 2020-09-11 |
US20200289549A1 (en) | 2020-09-17 |
BR112020009444A2 (pt) | 2020-11-17 |
EP3717035C0 (en) | 2023-10-25 |
IL274514A (en) | 2020-06-30 |
EP3717035B1 (en) | 2023-10-25 |
KR102436620B1 (ko) | 2022-08-25 |
US11266682B2 (en) | 2022-03-08 |
CN111526897A (zh) | 2020-08-11 |
IL274514B1 (en) | 2023-12-01 |
KR20200091426A (ko) | 2020-07-30 |
JP2021511092A (ja) | 2021-05-06 |
CA3098243A1 (en) | 2019-06-06 |
WO2019104407A1 (en) | 2019-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dong et al. | Nanotechnology shaping stem cell therapy: Recent advances, application, challenges, and future outlook | |
Genchi et al. | Smart materials meet multifunctional biomedical devices: Current and prospective implications for nanomedicine | |
Matsuoka et al. | Hyperthermia using magnetite cationic liposomes for hamster osteosarcoma | |
Oliveira et al. | Hydrogel-based scaffolds to support intrathecal stem cell transplantation as a gateway to the spinal cord: clinical needs, biomaterials, and imaging technologies | |
CN110123842B (zh) | 一种外泌体缓释体系及其构建方法与应用 | |
Go et al. | Multifunctional biodegradable microrobot with programmable morphology for biomedical applications | |
Avugadda et al. | Esterase-cleavable 2D assemblies of magnetic iron oxide nanocubes: Exploiting enzymatic polymer disassembling to improve magnetic hyperthermia heat losses | |
Cai et al. | Hybrid cell membrane-functionalized biomimetic nanoparticles for targeted therapy of osteosarcoma | |
Chen et al. | Adhesive and injectable hydrogel microspheres for inner ear treatment | |
Zhang et al. | The application of nanomaterials in stem cell therapy for some neurological diseases | |
Gonçalves et al. | Magnetic responsive cell-based strategies for diagnostics and therapeutics | |
Feng et al. | Recent progress of nanomedicine in the treatment of central nervous system diseases | |
Cheng et al. | Rabies virus glycoprotein-mediated transportation and T cell infiltration to brain tumor by magnetoelectric gold yarnballs | |
Kubinová | Biomaterials and magnetic stem cell delivery in the treatment of spinal cord injury | |
Daniels et al. | Synthesis and characterization of pHLIP® coated gold nanoparticles | |
Huang et al. | 3D gradient and linearly aligned magnetic microcapsules in nerve guidance conduits with remotely spatiotemporally controlled release to enhance peripheral nerve repair | |
Ballerini et al. | Nanomaterial applications in multiple sclerosis inflamed brain | |
Parimi et al. | Nanomagnet-facilitated pharmaco-compatibility for cancer diagnostics: Underlying risks and the emergence of ultrasmall nanomagnets | |
Liu et al. | Helical hydrogel micromotors for delivery of neural stem cells and restoration of neural connectivity | |
JP7105505B2 (ja) | 生体組織への局所曝露方法、組織置換アプリケーターおよび多孔質ポリテトラフルオロエチレンの使用 | |
Choi et al. | In situ magnetic alignment and cross-linking of injectable microparticles into centimeter-scale fibers for efficient myoblast alignment and in vivo fiber formation | |
Marino et al. | Innovative nanotechnology tools for the functional control and tracking of human stem cells | |
EA044877B1 (ru) | Способ локального воздействия на биологические ткани, тканезамещающий аппликатор и применение пористого политетрафторэтилена (варианты) | |
Song | In vivo assessment of stem cells for treating neurodegenerative disease: Current approaches and future prospects | |
Ovejero et al. | Nanoparticles for Neural Applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201106 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211005 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20211216 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211217 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20211217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220302 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220621 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220705 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7105505 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |